Small molecule targeting of protein-protein interaction (PPI) interfaces has long been a difficult problem. At DiCE, we leverage unique insight using a variety of cutting-edge technologies to effectively prosecute previously intractable PPI targets. By combining deep knowledge of target biology and medicinal chemistry, we have demonstrated that small molecules can effectively target oligomer interfaces.
In order to provide the greatest benefit to human health, we have chosen to focus on therapeutic opportunities that have been clinically and commercially validated by successful antibodies, thus enabling us to front-load risk onto lead optimization, where we have strong core competencies. We are confident that this approach will allow us to rapidly deliver safe and effective medicines to patients.